This database contains 472 studies, archived under the term: "Pharmaceutical Interventions"
Click here to filter this large number of results.
Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease – protocol for a controlled, randomized double-blinded trial
Egefjord, Lærke,
Gejl, Michael,
Møller, Arne,
Brændgaard, Hans,
Gottrup, Hanne,
Antropova, Olga,
Møller, Niels,
Poulsen, Henrik E.,
Gjedde, Albert,
Brock, Birgitte,
Rungby, Jørgen
Introduction: Type 2 diabetes (DM-2) increases the risk of developing Alzheimer´s disease (AD), and patients with AD are more likely to develop DM-2. DM-2 and AD share some pathophysiological features. In AD, amyloid-β (Aβ) is accumulated as extracellular plaques in the gray matter of the brain, while in DM-2 islet amyloid polypeptide (IAPP) is accumulated […]
Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease
Burstein, Aaron H,
Zhao, Qinying,
Ross, Joel,
Styren, Scot,
Landen, Jaren W.,
Ma, Wendy W.,
McCush, Fred,
Alvey, Christine,
Kupiec, James W.,
Bednar, Martin M.
Objective: Ponezumab (PF-04360365) is a humanized anti-amyloid beta (Aβ) monoclonal antibody designed for treatment of Alzheimer disease (AD). A single 2-hour intravenous infusion of 0.1 to 10 mg/kg was previously shown to be safe and well tolerated in subjects with mild to moderate AD, with measurable effects on plasma and cerebrospinal fluid Aβ. This phase […]
Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment
Bakker, Arnold,
Krauss, Gregory L.,
Albert, Marilyn S.,
Speck, Caroline L.,
Jones, Lauren R.,
Stark, Craig E.,
Yassa, Michael A.,
Bassett, Susan S.,
Shelton, Amy L.,
Gallagher, Michela
Elevated hippocampal activation is observed in conditions that confer risk for Alzheimer’s disease, including amnestic mild cognitive impairment (aMCI). Studies in relevant animal models have indicated that overactivity in selective hippocampal circuits contributes to cognitive impairment. Here, we tested the effect of reducing hippocampal activation in aMCI. Under placebo treatment, hippocampal activation in the dentate […]
Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer’s patients–an open-label trial
Kennelly, Sean,
Abdullah, Laila,
Kenny, Rose Anne,
Mathura, Venkat,
Luis, Cheryl A.,
Mouzon, Benoit,
Crawford, Fiona,
Mullan, Michael,
Lawlor, Brian
Background: Evidence suggests that dihydropyridine calcium channel blockers may be useful in preventing and treating Alzheimer’s disease (AD).; Objective: In an open-label trial of safety and tolerability of nilvadipine in patients with AD, we examined cognition and executive function over a short time period to determine an influence of nilvadipine on these outcomes.; Method: We […]
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease
Blennow, Kaj,
Zetterberg, Henrik,
Rinne, Juha O.,
Salloway, Stephen,
Wei, Jenny,
Black, Ronald,
Grundman, Michael,
Liu, Enchi
Background: Given the slow and variable clinical course of Alzheimer disease, very large and extended clinical trials are needed to identify a beneficial clinical effect of disease-modifying treatments. Therefore, biomarkers are essential to prove that an anti-β-amyloid (Aβ) drug candidate affects both Aβ metabolism and plaque load as well as downstream pathogenic mechanisms.; Objective: To […]
A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington’s disease
We examined the effects of 3 dosages of pridopidine, a dopamine-stabilizing compound, on motor function and other features of Huntington’s disease, with additional evaluation of its safety and tolerability. This was a randomized, double-blind, placebo-controlled trial in outpatient neurology clinics at 27 sites in the United States and Canada. Two hundred twenty-seven subjects enrolled from […]